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A b s T r A C T
background: Type 2 diabetes (dM2) is associated 
with a greater risk of heart failure. The mechanisms 
underlying this association remain controversial and 
include diabetes-associated hypertension and obesity, 
impaired small and large artery function, and a distinct 
metabolic cardiomyopathy related to hyperglycaemia/
hyperinsulinaemia. The proximate causes of heart 
failure are left ventricular (lV) systolic dysfunction (sdf) 
and diastolic dysfunction (ddf). We investigated, in a 
population-based cohort (n=746), the association between 
glucose tolerance status and sdf and ddf. 
Methods and results: The study population consisted of 
274 individuals with normal glucose metabolism (NGM), 
174 with impaired glucose metabolism (iGM) and 298 with 
dM2 (mean age 68.5 years). All participants underwent an 
lV echocardiogram. sdf was defined as ejection fraction 
<55%. ddf was determined by a sum score of peak A 
velocity (abnormal, ≥97 cm/s), the difference between Apv 
and Amv duration (≥41 ms), and left atrial volume (≥57 ml), 
where cut-off values were based upon the 90th percentile 
in NGM. in addition, we analysed the ratio of early to late 
diastolic filling (E/A ratio) on a continuous scale using 
linear regression analyses. The age- and sex-standardised 
prevalences in NGM, iGM and dM2 were 13, 14 and 30% 
for sdf, and 26, 36 and 47% for ddf (P(trend) for both 
<0.001). After adjustment for sex, age, hypertension, 
body mass index, prior cardiovascular disease and (micro)
albuminuria, dM2 was significantly associated with both 
sdf (odds ratio (95% Ci) 2.04 (1.24 to 3.36)) and ddf (2.42 
(1.63 to 3.60)) (90th percentile definition). This was also 
true for the analyses with the E/A ratio on a continuous 
scale (regression coefficient b (95% Ci) -0.05 (-0.09 to 
-0.01). After adjustment for sex, age, hypertension, body 
mass index, prior cardiovascular disease and (micro)
albuminuria iGM was not significantly associated with 
sdf (odds ratio (95% Ci) 1.04 (0.58 to 1.88)) or ddf 
(1.33 (0.86 to 2.06)) using the definition based upon 
the 90th percentile. However, iGM was significantly 
associated with ddf if the E/A ratio was analysed on a 
continuous scale (regression coefficient b (95% Ci) -0.05 
(-0.10 to -0.01). Additional adjustment for brachial artery 
flow-mediated vasodilation or arterial stiffness, as measures 
of large artery function, did not materially alter the results. 
Hyperglycaemia and hyperinsulinaemia together explained 
~30% of the association of dM2 with sdf and ~40% of that 
with ddf. 
Conclusion: dM2 is independently associated with a 
2.0-fold greater risk of sdf and a 2.4-fold greater risk of 
ddf. iGM was not associated with sdf, and the association 
with ddf was limited to the E/A ratio. These observations 
may therefore explain the increased risk of systolic and 
diastolic heart failure in elderly individuals with dM2. 
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i N T r o d U C T i o N 
Type 2 diabetes (DM2) is associated with an increased 
risk of heart failure.1-4 The mechanisms underlying this 
association remain controversial, and there may be at 
least three possibilities. First, DM2 is often associated 
with hypertension and obesity, and these risk factors 
may in part account for the association of DM2 with 
heart failure.5-7 Second, DM2 may lead to heart failure by 
impairing large and small artery function, because DM2 
causes atherothrombotic coronary artery disease,8 diabetic 
microangiopathy,9 small and large artery endothelial 
dysfunction10,11 and increased arterial stiffness.12,13 Third, 
DM2 may cause a distinct metabolic cardiomyopathy 
related to hyperglycaemia and/or hyperinsulinaemia.14-16
The proximate causes of heart failure are left ventricular 
(LV) systolic and diastolic dysfunction. Previous studies 
on the association between glucose metabolism and LV 
function have not yielded consistent results, possibly 
because these studies were relatively small,17-27 had 
targeted selected populations,18,19,22-24,28 or dealt exclusively 
with DM2,17-28 whilst population-based studies focused 
primarily on LV structure.29-33 In addition, it is unclear 
whether LV dysfunction can also be detected in impaired 
glucose metabolism (IGM), i.e. impaired fasting glucose 
or impaired glucose tolerance.29,34-36 The latter is of 
particular importance as investigations in IGM could 
give insight into the early development of DM2-related LV 
dysfunction.
In view of these considerations, we investigated, in a 
population-based cohort (n=746), the association between 
deteriorating glucose tolerance status on the one hand 
and echocardiographically determined LV systolic and 
diastolic function on the other. In addition, we explored the 
mechanisms underlying any such associations. 
M E T H o d s 
study population
For the present investigation we used data from the 2000 
follow-up examination of the Hoorn Study37 and data 
from the Hoorn Screening Study,38 both of which were 
population-based. Details have been described elsewhere.13 
The entire study population consisted of 822 individuals 
(290 with a normal glucose metabolism (NGM), 187 
with IGM, and 345 with DM2). Glucose tolerance status 
was determined by a single oral glucose tolerance test 
according to the 1999 WHO criteria (i.e. NGM: fasting 
glucose <7.0 mmol/l and post-load glucose <7.8 mmo/l; 
IGM: fasting glucose ≥7.0 mmol/l and postload glucose 
≤11.1 mmol/l; DM2: fasting glucose ≥7.0 mmol/l and 
post-load glucose >11.1 mmol/l).
Echocardiography
A single ultrasound research technician blinded to the 
participants’ clinical or glucose tolerance status obtained 
an LV echocardiogram according to a standardised 
protocol consisting of 2D, M-mode, spectral and colour 
flow Doppler recordings, with the use of an ultrasound 
scanner (HP SONOS 5500; 2-4 Mhz transducer, Andover, 
Massachusetts, USA). 2D recordings were performed in 
parasternal long- and short-axis views, and apical four- and 
two-chamber views.39 Pulsed-Doppler spectral recordings 
were obtained with the sample volume placed at the tips 
of the mitral leaflets and, for the pulmonary venous 
flow, at the orifice of the right upper pulmonary vein. 
All recordings were digitally stored and analysed off-line 
according to international guidelines.39 
We measured left atrial and ventricular diastolic and 
systolic diameters, and posterior wall (PWT) and interven-
tricular septum thicknesses (IVS) from M-mode. Left atrial 
and ventricular systolic and diastolic volumes and ejection 
fraction were calculated from the apical four chamber view 
using the modified Simpson formula. Left ventricular 
mass was calculated as 0.8(1.04) ((EDD + IVS + PWT)3 
- EDD3) + 0.6 (in grams), and relative wall thickness as 
(IVS + PWT)/EDD. From the transmitral pulsed-Doppler 
recordings, we obtained peak E and A velocities, the ratio of 
early to late diastolic filling (E/A ratio) and the deceleration 
time E. Isovolumetric relaxation time was measured as 
the time from the end of aortic flow to the onset of mitral 
flow. From the pulmonary vein pulsed-Doppler recordings, 
we obtained the pulmonary vein flow A wave duration 
(Apv) and the duration of the A wave (Amv) over the mitral 
valve.40 Each echocardiogram was inspected afterwards 
by a senior cardiologist blinded to the participants’ clinical 
or glucose tolerance status to monitor quality of both 
recordings and readings.
systolic and diastolic lV function
Normal LV systolic function was defined as ejection 
fraction ≥55%, and LV systolic dysfunction as ejection 
fraction <55%.39 Normal LV diastolic function was defined 
as a sum score of 0 points, and LV diastolic dysfunction 
as a sum score ≥1 point, on the basis of the sum of three 
indices of late diastolic function, i.e., peak A velocity (0 
points if <97 cm/s, 1 point if ≥97 cm/s); difference between 
Apv and Amv duration (0 points if <41 ms; 1 point if ≥41 
ms); and left atrial volume (0 points if <57 ml, 1 point if 
≥57 ml), where the cut-off values were 90th percentile in 
individuals with NGM. In addition, we analysed the E/A 
ratio on a continuous scale.
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other measurements
Health status, medical history, medication use and smoking 
habits were assessed by questionnaire.37,38 We determined 
systolic and diastolic pressure, hypertension, glucose, 
glycated haemoglobin, insulin, serum total, high-density 
and low-density lipoprotein cholesterol, serum triglycerides, 
serum creatinine, (micro)albuminuria (as an estimate 
of (diabetic) microangiopathy), body mass index (BMI), 
waist-to-hip ratio and ankle-brachial pressure index as 
described elsewhere.37,38 Insulin resistance was calculated 
according to the HOMA model.41 Resting electrocardiograms 
were automatically coded according to the Minnesota Code.15 
Hypertension, prior cardiovascular disease and (micro)
albuminuria were defined as described previously.13,42 
Endothelial function was estimated from noninvasive 
brachial flow-mediated vasodilation,11,43 and central and 
peripheral artery stiffness from arterial ultrasonography, 
echocardiography and radial applanation tonometry.12,13
statistical analyses
All analyses were carried out with SPSS (SPSS, Chicago, 
USA). We used analyses of covariance (ANCOVA), with 
linear contrast, to investigate trends in left atrial and 
ventricular mean values across categories of glucose 
tolerance. All statistically significant trends were tested 
on whether they deviated from linearity. The associations 
between glucose tolerance status and LV function were 
investigated with the use of logistic regression, in which LV 
dysfunction was classified as absent vs present (the 90th 
percentile definition). In addition, we analysed the E/A ratio 
on a continuous scale using linear regression analyses. In 
both these statistical methods glucose tolerance status was 
defined by dummy variables for IGM and DM2 with NGM as 
reference category. We first analysed the associations without 
any adjustments (crude model) and then with adjustments 
for potential confounders (adjusted models). As LV function 
is known to be affected by sex, age, hypertension and prior 
Table 1. Characteristics of the study population according to glucose tolerance status
Normal glucose 
metabolism
impaired glucose 
metabolism
Type 2 diabetes 
mellitus
P(trend)
No. m/f 274 (133/141) 174 (86/88) 298 (160/138) --
Age years 68.5 ± 6.0 70.0 ± 6.2 66.9 ± 8.2 --
Systolic pressure mmHg 137 ± 20 144 ± 16 148 ± 20 <0.001
Diastolic pressure mmHg 75 ± 9 78 ± 9 79 ± 9 <0.001
Pulse pressure mmHg 62 ± 16 67 ± 13 69 ± 15 <0.001
Mean pressure mmHg 95 ± 11 100 ± 10 102 ± 11 <0.001
Hypertension % 56 71 81 <0.001
Antihypertensive medication % 25 35 51 <0.001
Total cholesterol mmol/l 5.8 ± 1.0 5.8 ± 1.0 5.5 ± 1.1 0.003
HDL cholesterol mmol/l 1.5 ± 0.4 1.4 ± 0.4 1.2 ± 0.3 <0.001
LDL cholesterol mmol/l 3.7 ± 0.9 3.7 ± 0.9 3.5 ± 0.9 0.001
Triglycerides mmol/l 1.2 (0.9-1.5) 1.3 (1.0-1.8) 1.6 (1.2-2.2) <0.001
Lipid-lowering medication % 13 17 20 0.03
Fasting glucose mmol/l 5.4 ± 0.4 6.1 ± 0.5 7.7 ± 1.7 <0.001
Post-load glucose mmol/l 5.6 ± 1.1 8.0 ± 1.6 11.7 ± 2.7 <0.001
Glycated haemoglobin % 5.7 ± 0.4 5.9 ± 0.4 6.6 ± 0.9 <0.001
Fasting insulin* pmol/l 46.0 (35.0-59.0) 65.5 (49.3-87.5) 83.5 (56.0-113) <0.001
HOMA-IR* AU 1.57 (1.16-2.04) 2.53 (1.87-3.19) 3.66 (2.54-5.47) <0.001
Height cm 169 ± 9 170 ± 9 169 ± 9 0.99
Weight kg 75 ± 12 80 ± 13 83 ± 14 <0.001
Body mass index kg/m2 26.1 ± 3.4 27.9 ± 4.0 28.9 ± 4.2 <0.001
Waist-to-hip ratio -- 0.90 ± 0.09 0.94 ± 0.08 0.96 ± 0.10 <0.001
Prior CVD % 42 47 53 0.01
Serum creatinine µmol/l 94.5 ± 14.1 94.8 ± 15.2 94.9 ± 19.5 0.80
(Micro) albuminuria % 10 14 19 <.001
Smoking % 15 18 13 0.38
SAC ml/mmHg 1.1 ± 0.3 1.0 ± 0.3 0.9 ± 0.3 <0.001
Carotid distensibility 10-3
kPa-1
12.8 ± 4.2 11.6 ± 4.6 10.5 ± 4.3 <0.001
Brachial FMD# mm 0.20 ± 0.15 0.19 ± 0.18 0.13 ± 0.17 <0.001
data are reported as mean ± standard deviation or median (interquartile range). * n=733 as 13 individuals were on insulin therapy.  
sAC = systemic arterial compliance (n=695); data on other measures of central and peripheral arterial stiffness have been reported elsewhere.12,13 
fMd = flow-mediated vasodilation (n=543).11
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cardiovascular disease (including coronary artery disease), 
these variables were considered first in the adjusted models. 
After we had assessed the main effects, interaction terms 
were used to investigate whether the association between 
glucose tolerance status and left ventricular function differed 
according to sex. Individuals with impaired fasting glucose 
(n=64) and impaired glucose tolerance (n=116) did not 
significantly differ from each other with regard to any of the 
analyses and were therefore combined. 
Results are expressed as odds ratios with their 95% 
confidence interval. P values <0.05 were considered 
statistically significant. 
r E s U l T s 
Echocardiographic examinations
Of the 822 participants, 53 did not undergo the full 
standardised echocardiographic protocol for logistical 
reasons and in 23, a qualitatively satisfactory 
echocardiogram could not be obtained either due to a high 
body mass index (n=20; body mass index of subjects with 
an echocardiographic examination vs those without: 27.3 
± 3.8 kg/m2 vs 36.4 ±7.9; p<0.001) or a poor transthoracic 
window (n=3). Further analyses were therefore based on 
746 individuals (table 1). 
Glucose tolerance and lV systolic function 
Ejection fraction and fractional shortening decreased 
with deteriorating glucose tolerance status (P(trend) for 
both <0.001). LV end-systolic volume increased with 
deteriorating glucose tolerance status (P(trend) = 0.007). 
The prevalence of LV systolic dysfunction (standardised for 
age and sex) in NGM, IGM and DM2 was 13, 14 and 30%, 
respectively (P(trend) <0.001) (table 2). 
Glucose tolerance and lV diastolic function
The prevalence in NGM, IGM and DM2 of peak A velocity 
≥97 cm/s was 10% (by definition), 16 and 22%, respectively; 
of difference between Apv and Amv duration ≥41 ms, 10% 
(by definition), 11 and 14%; and of left atrial volume ≥57 ml, 
10% (by definition), 14 and 24%. The prevalence of diastolic 
dysfunction (standardised for age and sex) in NGM, IGM 
and DM2 was 26, 36 and 47% (P(trend) <0.001). The E/A 
ratio decreased with deteriorating glucose tolerance (P(trend) 
= 0.007) (table 2).
odds ratios for lV systolic and diastolic dysfunction
As compared with NGM, DM2 was significantly associated 
with LV systolic dysfunction (OR (95% CI), 2.44 (1.55 to 
3.85)). The association remained statistically significant 
after additional adjustment for sex, age, hypertension, 
prior cardiovascular disease, body mass index and (micro)
Table 2. Left ventricular function according to glucose tolerance status
Normal glucose 
metabolism
impaired glucose 
metabolism
Type 2 diabetes 
mellitus
P(trend)
Prevalence of left ventricular dysfunctiona 
Systolic dysfunction (%) 13 14 30 <0.001
Diastolic dysfunction (%) 26 36 47 <0.001
Estimates of systolic function
Left ventricular end-systolic volume (ml) 38 (1) 38 (1) 42 (1.0)† 0.007
Ejection fraction 0.63 (0.01) 0.62 (0.01) 0.59 (0.01)†‡ <0.001
 % of individuals with ejection fraction <55 13 14 30†‡ <0.001
Fractional shortening  46.9 (0.3) 46.5 (0.4) 44.7 (0.3)†‡ <0.001
Estimates of diastolic function
Peak E velocity (cm/s) 64.7 (1.0) 65.0 (1.3) 69.1 (1.0)†‡ 0.002
Peak A velocity (cm/s) 77.0 (1.0) 81.2 (1.3)# 87.2 (1.0)†‡ <0.001
 % of individuals with peak A velocity ≥97 10 16# 22†‡ <0.001
E/A ratio 0.87 (0.01) 0.82 (0.02) 0.82 (0.01)† 0.007
Deceleration time E (ms) 244 (3) 237 (4) 241 (3) 0.53
Duration of Amv (ms) 124 (1) 121 (1) 123 (1) 0.70
Duration of Apv (ms) 139 (1) 136 (2) 144 (1)
†‡ 0.12
 % of individuals with Apv-Amv ≥41 10 11 14†‡ 0.20
Isovolumetric relaxation time (ms) 130 (3) 132 (4) 138 (3) 0.10
Left atrium volume (ml) 42 (1) 43 (1) 51 (1)†‡ <0.001
 % of individuals with left atrium volume ≥57 10 14 24†‡ <0.001
Left ventricular end-diastolic volume (ml) 100 (1) 100 (2) 100 (1) 0.96
data are reported as mean values (standard error) adjusted for age and sex, whereas the percentages of the individual measurements of left 
ventrical function were standardised for age and sex, with normal glucose metabolism as reference group. a for definitions see methods.  
†p<0.05 vs normal glucose metabolism. ‡p<0.05 vs impaired glucose metabolism. #p<0.05 vs =normal glucose metabolism.
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albuminuria (OR, 2.04 (1.24 to 3.36)). IGM was not 
statistically significantly associated with LV systolic 
dysfunction (table 3 and figure 1).
As compared with NGM, DM2 was significantly associated 
with LV diastolic dysfunction (OR, 2.54 (1.77 to 3.65)). 
The association remained statistically significant after 
additional adjustment for sex, age, hypertension, prior 
cardiovascular disease, body mass index and (micro)
albuminuria (OR, 2.42 (1.63 to 3.60)). IGM was not 
statistically significantly associated with LV diastolic 
dysfunction after adjustment for hypertension and body 
mass index.
If we repeated the analyses with peak E, peak A and E/A 
ratio as continuous variables using regression analyses 
our results were not materially altered. However, the 
association between E/A ratio (i.e., a measure composed 
of both ‘early’ and ‘late’ diastolic dysfunction) and IGM 
reached statistical significance even after adjustment 
for prior cardiovascular disease and microalbuminuria 
(regression coefficient b (95% CI) -0.05 (-0.10 to -0.01) 
and -0.05 (-0.09 to -0.01) respectively (table 4; models 6 
and 7). 
Results were similar when additionally adjusted for brachial 
flow-mediated vasodilation or measures of central and 
peripheral arterial stiffness (table 3, models 8 to 10). 
To estimate the contribution of hyperglycaemia, 
hyperinsulinaemia and insulin resistance to the association 
between glucose tolerance status and left ventricular 
function, we compared the above analyses with those 
additionally adjusted for HbA1c (or fasting or postload 
glucose) and for insulin and insulin resistance. This 
showed that hyperglycaemia and hyperinsulinaemia 
explained 28% of the association of glucose tolerance 
with LV systolic dysfunction and 39% of that with LV 
diastolic dysfunction, with both variables contributing 
approximately equally (data not shown). 
Additional analyses
The results of the logistic regression analyses for LV systolic 
dysfunction were not materially altered if the cut-off value 
for ejection fraction was set at 45% (data not shown). 
The impact of a deteriorating glucose tolerance status 
on left ventricular function might be worse in women.1 
However, we found no interaction between DM2 and sex 
Table 3. Adjusted odds ratios for left ventricular dysfunction according to glucose tolerance status
Model Added variables systolic dysfunction diastolic dysfunction
impaired glucose 
metabolism
Type 2 diabetes 
mellitus
impaired glucose 
metabolism
Type 2 diabetes 
mellitus
1. Crude 1.10 (0.62 to 1.95) 2.44 (1.55 to 3.85) 1.63 (1.07 to 2.46) 2.54 (1.77 to 3.65)
2. Model 1 + sex 1.08 (0.61 to 1.93) 2.43 (1.53 to 3.88) 1.63 (1.07 to 2.46) 2.54 (1.77 to 3.65)
3. Model 2 + age 1.10 (0.61 to 1.96) 2.38 (1.49 to 3.80) 1.50 (0.98 to 2.29) 2.98 (2.05 to 4.34)
4. Model 3 + hypertension 1.06 (0.59 to 1.91) 2.22 (1.37 to 3.58) 1.41 (0.92 to 2.16) 2.63 (1.78 to 3.87)
5. Model 4 + body mass index 1.06 (0.59 to 1.90) 2.13 (1.31 to 3.46) 1.33 (0.86 to 2.06) 2.46 (1.65 to 3.65)
6. Model 5 + prior cardiovascular disease 1.04 (0.58 to 1.88) 2.08 (1.26 to 3.41) 1.33 (0.86 to 2.06) 2.44 (1.64 to 3.63)
7. Model 5 + (micro-)albuminuria 1.03 (0.57 to 1.86) 2.04 (1.24 to 3.36) 1.33 (0.86 to 2.05) 2.42 (1.63 to 3.60)
8. Model 5 + carotid distensibility* 0.98 (0.50 to 1.93) 2.02 (1.15 to 3.52) 1.38 (0.79 to 2.08) 2.20 (1.43 to 3.37)
9. Model 5 + systemic compliance* 0.89 (0.45 to 1.77) 2.85 (1.67 to 4.84) 1.27 (0.77 to 2.10) 2.48 (1.59 to 3.87)
10. Model 5 + flow mediated dilation* 1.08 (0.54 to 2.16) 3.26 (1.86 to 5.73) 1.31 (0.80 to 2.14) 2.32 (1.49 to 3.62)
results are expressed as odds ratios (95% Ci). Normal glucose metabolism serves as reference category. *for carotid distensibility: n=724; for 
systemic compliance: n=612; for flow-mediated dilatation: n=605.
figure 1. Adjusted odds ratios and their 95% 
confidence interval for left ventricular dysfunction 
across categories of glucose tolerance 
Systolic dysfunction Diastolic dysfunction
NGM
1.00
1.03
(0.57-1.86)
2.04
(1.24-3.36)
1.00
1.33
(0.86-2.05)
2.42
(1.63-3.60)
0.1
1
10
IGM DM2
NGM = normal glucose metabolism; iGM = impaired glucose 
metabolism; dM2 = type 2 diabetes mellitus. NGM served 
as reference category. Adjustments were made for age, sex, 
hypertension, body mass index, prior cardiovascular disease, and 
(micro)albuminuria.
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(all p values ≥0.13), which means that within our data 
no significant sex differences existed in the relationship 
between left ventricular function and glucose tolerance 
status. Results were not materially altered if we replaced 
hypertension by any of the other blood pressure variables, 
or if we replaced body mass index by body surface area or 
waist-to-hip ratio (data not shown).
The results of the logistic regression analyses for LV 
diastolic dysfunction were not materially altered if we 
excluded those with an ejection fraction <45% (n=23) (data 
not shown). 
Results were also similar when additionally adjusted for 
lipid profile, use of lipid-lowering or antihypertensive 
medication (including ACE inhibitors), smoking, serum 
creatinine and LV wall motion abnormalities (data not 
shown). 
If we replaced the P90 cut-off values for LA volume and 
Apv-Amv wave duration for published cut-off values
44,45 
or chose the P95 as cut-off value, our results were not 
materially altered. 
d i s C U s s i o N
This study had four main results. First, as compared 
with NGM, DM2 was associated with a 2.0-fold greater 
risk of LV systolic dysfunction and a 2.4-fold greater 
risk of LV diastolic dysfunction. Second, these higher 
risks could not be explained by higher blood pressure 
or greater obesity, which are often observed in DM2, 
nor by DM2-associated impairment of large and small 
artery function, as estimated from the prevalence of prior 
cardiovascular disease and (micro)albuminuria, and from 
large artery endothelium-dependent vasodilation and 
stiffness. Third, a considerable part of LV dysfunction in 
DM2 (about 30 to 40%) was explained by hyperglycaemia 
and hyperinsulinaemia. Fourth, in this elderly population, 
IGM was not significantly associated with impaired 
LV function using the definition based upon the 90th 
percentile of diastolic dysfunction (DDF) parameters, but 
was associated with DDF using linear regression analyses 
with the E/A ratio on a continuous scale. These findings 
may thus explain why DM2 increases the risk of systolic 
and diastolic heart failure, and additionally argue in 
favour of a distinct metabolic cardiomyopathy in elderly 
individuals with DM2. In elderly individuals with IGM 
this is less clear. 
Our study was comprehensive and had important 
advantages over previous studies on the association 
between glucose tolerance and LV function, which were 
relatively small,17-27 targeted selected populations,18,19,22-24,28 
or dealt exclusively with DM217-28 whilst population-based 
studies focused primarily on LV structure in relation to LV 
systolic dysfunction.29-33 
Our results on systolic dysfunction are in concordance with 
a study by Celentano et al.,17 who studied 64 telephone 
company employees, the HyperGen Study30 and two Strong 
Heart Study reports.29,31 However, the Cardiovascular 
Health Study (CHS),32 somewhat unexpectedly, did not 
observe systolic dysfunction in DM2. 
Our study is the first to observe a clear association between 
DM2 and LV diastolic dysfunction in a large (Caucasian) 
general population-based study, designed to investigate 
the differences between NGM, IGM and DM2. Previous 
studies18,19,22,25,29,32,36 may have failed to detect a consistent 
association of DM2 with LV diastolic dysfunction because 
of the use of echocardiographic measures of both early and 
late LV diastolic filling (i.e., the E/A ratio) which can be 
Table 4. Adjusted b-coefficients for conventional measures of left ventricular diastolic dysfunction
Model Added variables Peak E velocity (cm/s) Peak A velocity (cm/s) E/A ratio (--)
impaired
glucose 
metabolism
Type 2
diabetes 
mellitus
impaired
glucose 
metabolism
Type 2
diabetes 
mellitus
impaired
glucose 
metabolism
Type 2
diabetes 
mellitus
1. Crude -0.05  
(-3.31 to 3.21)
4.59  
(1.76 to 7.41)
5.67  
(2.08 to 9.25)
8.40  
(5.29 to 11.52)
-0.07  
(-0.12 to -0.03)
-0.03  
(-0.08 to 0.01)
2. Model 1 + sex -0.00  
(-3.21 to 3.20)
4.90  
(2.12 to 7.68)
5.73  
(2.26 to 9.21)
8.88  
(5.86 to 11.90)
-0.07  
(-0.12 to -0.03)
-0.04  
(-0.08 to 0.01)
3. Model 2 + age 0.31  
(-2.89 to 3.51)
4.53  
(1.76 to 7.30)
4.52  
(1.22 to 7.82)
10.23  
(7.36 to 13.10)
-0.06  
(-0.10 to -0.01)
-0.05  
(-0.09 to -0.01)
4. Model 3 + hypertension -0.07  
(-3.29 to 3.15)
4.78  
(0.90 to 6.66)
3.90  
(0.60 to 7.20)
8.99  
(6.03 to 11.94)
-0.06  
(-0.10 to -0.01)
-0.05  
(-0.09 to -0.01)
5. Model 4 + body mass index -0.80  
(-4.04 to 2.43)
2.80  
(-0.13 to 5.72)
3.26  
(-0.75 to 6.59)
8.15  
(5.13 to 11.17)
-0.05  
(-0.10 to -0.01)
-0.05  
(-0.09 to -0.01)
6. Model 5 + prior  
cardiovascular disease 
-0.62  
(-3.88 to 3.12)
2.12  
(-0.89 to 5.13)
2.93  
(-0.40 to 6.25)
7.30  
(4.25 to 10.36)
-0.06  
(-0.10 to -0.01)
-0.05  
(-0.09 to -0.01)
7. Model 5 + (micro) 
albuminuria
-0.82  
(-4.06 to 2.43)
2.75  
(-0.20 to 5.71)
3.19  
(-0.14 to 6.51)
7.89  
(4.86 to 10.92)
-0.05  
(-0.10 to -0.01)
-0.05  
(-0.09 to -0.00)
results are expressed as b-coefficients (95% Ci). Normal glucose metabolism serves as reference category.
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hampered by the phenomenon of ‘pseudo-normalisation’ 
(i.e., an apparently normal LV diastolic filling pattern 
due to increased LA pressure, as a direct consequence of 
decreased LV compliance).46 Interestingly, in our study a 
significant relationship did exist between the E/A ratio and 
glucose tolerance status. The reason for this discrepancy is 
not clear. However, to further overcome the phenomenon 
of pseudo-normalisation, we also analysed measurements 
of late diastolic performance (i.e., peak A velocity, Apv-Amv 
duration and LA volume) and combined these into a 
simple sum score, which has the advantage of excluding 
active myocardial relaxation during diastole46 and thus 
providing optimal characterisation of passive stiffness of 
the LV chamber.
The mechanisms linking DM2 to systolic and diastolic LV 
dysfunction are incompletely understood. We found no 
evidence that DM2-associated hypertension and obesity 
played a role. In addition, our data do not support an 
important role for DM2-induced impairment of large 
and small artery function. However, the validity of this 
conclusion depends on the accuracy of the estimates of 
arterial function we used. For example, we used brachial 
artery endothelium-dependent vasodilation and (micro)
albuminuria as estimates of coronary epicardial and 
microvascular function, respectively, and this may be 
insufficiently precise. Therefore, future studies to address 
these issues should use more sophisticated techniques.
Interestingly, indices of hyperglycaemia and hyperinsulinaemia 
(or insulin resistance) explained about 30 to 40% of the 
association between DM2 and LV dysfunction, supporting 
the existence, in these elderly individuals, of a distinct 
metabolic cardiomyopathy.14,47,48 Hyperglycaemia and 
hyperinsulinaemia may impair LV function through 
several pathways, the relative importance of which is 
not completely understood. First, hyperglycaemia alters 
intracellular calcium homeostasis, leading to depressed 
contractile function.49,50 Second, hyperglycaemia increases 
oxidative and carbonyl stress,51 which may lead to a chronic, 
low-grade inflammatory response and cross-linking of 
myocardial proteins, which may promote myocardial 
fibrosis and impair LV compliance, effects that may 
be enhanced by the growth promoting properties of 
hyperinsulinaemia.52,53
It is not known whether IGM is independently associated 
with risk of heart failure. In our study, IGM was not 
associated with systolic dysfunction, and the association 
with diastolic dysfunction (based upon the 90th percentile 
definition) was explained by body mass index and 
hypertension. However, the association between IGM 
and DDF estimated from the E/A ratio remained after 
multivariate adjustment. Therefore, we conclude that IGM 
was associated with DDF but not with SDF. 
Our study had several limitations. First, we cannot exclude 
that our results have been influenced by the co-existence of 
(subclinical) cardiovascular disease affecting both LV wall 
motion and shape. To address this concern, we adjusted 
for prior cardiovascular disease in our statistical analyses. 
Moreover, our results were not materially altered when 
additionally adjusted for wall motion abnormalities (data 
not shown). Second, our results were obtained in elderly 
individuals. Therefore, we may have underestimated 
the association of LV dysfunction with glucose tolerance 
due to a healthy survivor effect. Finally, as our study was 
cross-sectional in nature, causality should be inferred 
with caution and it remains to be determined whether our 
results can be generalised to other ethnicities. 
We conclude that DM2 is independently associated with 
a 2.0 greater risk of LV systolic dysfunction and a 2.4 
greater risk of LV diastolic dysfunction. This may explain 
the increased risk of systolic and diastolic heart failure in 
elderly individuals with DM2. 
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